SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BLCO

Bausch & Lomb Corp (New York Stock Exchange:BLCO)

CA · Delayed Price · Currency is USD
Also listed: BLCO.TOHealthcare · Medical - Instruments & Supplies
$19.38-$1.31 (-6.33%)
 
Market cap
$6.93B
Insider Score
Health Score
Analyst consensus
Listed since
May 6, 2022
Website
Market Cap$6.93B+25.4%
Revenue (ttm)$5.41B+8.8%
Net Income-$111.00M+63.6%
EPS-$0.31+64.2%
Shares Out357.50M
PE Ration/a
Forward PE16.33
Dividendn/a
Ex-Dividend Daten/a
Volume871,551
Open$20.43
Previous Close$20.69
Day's Range$19.30 - $20.43
52-Week Range$14.65 - $21.40
Beta0.52
AnalystsHold
Price Target$21.75(+12.23%)
Earnings DateFeb 17, 2027

About BLCO

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

Address
520 Applewood Crescent, Vaughan, ON, L4K 4B4, CA
Market Cap
6.93 billion
Employees
13,000
Industrial Classification
Medical - Instruments & Supplies

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.49M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
2 Buy4 Hold0 SellAvg target $20.40 (+5.3%)

6 firms rating BLCO in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From BLCO’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-6.33%
5 Days
-7.71%
1 Month
+11.19%
6 Months
+21.73%
1 Year
+25.44%

$BLCO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BLCO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BLCO's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BLCO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BLCO Revenue by Segment or Geography

$2.38BTotal
Vision Care$774.00M32.48%
Devices$517.00M21.70%
OTC$477.00M20.02%
Pharmaceuticals$319.00M13.39%
Surgical$234.00M9.82%
Branded and Other Generics$58.00M2.43%
Other revenues$4.00M0.17%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BLCO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BLCO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BLCO

MGMTBallast Small/Mid Cap ETF$2.68M
ARWGArcher Growth ETF$363.32K
DFAXDimensional World ex U.S. Core Equity 2 ETF$314.12K
PDNInvesco RAFI Developed Markets ex-U.S. Small-Mid ETF$189.76K
GVLUGotham 1000 Value ETF$118.39K
DFICDimensional - International Core Equity 2 ETF$75.68K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BLCO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
79
News & Sentiment
20% of score
35

News check: BL1332 Phase 2 trial missed primary endpoint for post-surgical ocular pain, a significant clinical setback weighing on stock performance.

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-35.0 since Aug 21
0255075100Aug 21 — Insider Score 35.0Aug 22 — Insider Score 35.0Aug 23 — Insider Score 35.0Aug 24 — Insider Score 35.0Aug 25 — Insider Score 35.0Aug 26 — Insider Score 35.0Aug 27 — Insider Score 35.0Aug 28 — Insider Score 35.0Aug 29 — Insider Score 35.0Aug 30 — Insider Score 35.0Aug 31 — Insider Score 35.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 28.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MGMTBallast Small/Mid Cap ETF1.77%
GVLUGotham 1000 Value ETF0.05%
BKSEBNY Mellon US Small Cap Core Equity ETF0.04%
SHRTGotham Short Strategies ETF0.01%

Weight is the stock’s share of each fund’s holdings.